Skip to main content
Clearmind Medicine Inc. logo

Clearmind Medicine Inc. — Investor Relations & Filings

Ticker · CMND ISIN · CA1850534027 LEI · 8945006FVE3FLKX9BN50 US Manufacturing
Filings indexed 293 across all filing types
Latest filing 2026-05-05 Foreign Filer Report
Country CA Canada
Listing US CMND

About Clearmind Medicine Inc.

https://www.clearmindmedicine.com/

Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical company focused on developing novel psychedelic-derived therapeutics for under-served health problems. The company's primary objective is the research and development of treatments for binge behaviors and mental health conditions, with a lead focus on Alcohol Use Disorder (AUD). Its main therapeutic candidate, CMND-100, is based on the proprietary psychoactive molecule MEAI (5-Methoxy-2-aminoindane). MEAI is designed to produce an alcohol-like euphoric experience while reducing the desire to consume alcohol. The company is advancing CMND-100 in a Phase I/IIa clinical trial for AUD. Clearmind's development pipeline is supported by a portfolio of 19 patent families.

Recent filings

Filing Released Lang Actions
6-K - Clearmind Medicine Inc. (0001892500) (Filer)
Foreign Filer Report
2026-05-05 English
6-K - Clearmind Medicine Inc. (0001892500) (Filer)
Foreign Filer Report
2026-04-27 English
6-K - Clearmind Medicine Inc. (0001892500) (Filer)
Foreign Filer Report
2026-04-21 English
6-K - Clearmind Medicine Inc. (0001892500) (Filer)
Foreign Filer Report
2026-04-20 English
6-K - Clearmind Medicine Inc. (0001892500) (Filer)
Foreign Filer Report
2026-04-15 English
6-K - Clearmind Medicine Inc. (0001892500) (Filer)
Foreign Filer Report
2026-04-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.